Navigation Links
Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
Date:11/5/2007

alization agreement entered into in June 2006. HGS and Novartis will co-commercialize Albuferon in the United States and will share clinical development costs, U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization in the rest of the world and will pay HGS a royalty on those sales. Clinical development, commercial milestone and other payments to HGS could total as much as $507.5 million, including $132.5 million received to date.

About Hepatitis C

Hepatitis C is an inflammation of the liver caused by the hepatitis C virus (HCV). An estimated 170 million people worldwide are infected with the virus, including nearly 4 million people in the United States. When detectable levels of HCV persist in the blood for at least six months, a person is diagnosed with chronic hepatitis C. Hepatitis C virus can cause serious liver disease, leading to cirrhosis, primary liver cancer and even death.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancers.

For more information about HGS, please visit the Company's web site at

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015   Emerson Ecologics, LLC ... supplements, prescription products and natural health and ... with Anabolic Laboratories, a leading manufacturer of ... new partnership will allow Anabolic Laboratories to ... practitioner segments and provide customers with added ...
(Date:3/2/2015)... BUENA, N.J., March 2, 2015  IGI Laboratories, Inc. (NYSE ... announced its financial results for the fourth quarter and year ... to Date 2014 Highlights , Total revenues of ... of 104% over the same quarter in 2013 , ... 31, 2014, an increase of 85% over the same period ...
(Date:3/2/2015)... March 2, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... and full year ended December 31, 2014. Financial highlights for ... net loss of $5.3 million, or $0.04 per share. This ... of $22.0 million, or $0.19 per share, for the fourth ... include revenues of $75.3 million and a net loss of ...
Breaking Medicine Technology:Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 2Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 3IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 2IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 3IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 4IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 5IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 6IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 7IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 8IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 9IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 10IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 11IGI Laboratories Announces Fourth Quarter And Year End 2014 Results 12Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
... Mass., Aug. 26 Sermo ... physicians, today announced a free Sermo Report titled, " ... covers physician opinions about the introduction of an investigational ... to the results, 46% of physicians feel that ticagrelor ...
... Cardioxyl Pharmaceuticals, Inc. , a clinical-stage pharmaceutical ... disease, today announced that it has initiated a dose-defining ... for the treatment of patients with acute decompensated heart ... at the time of discharge from U.S. hospitals and ...
Cached Medicine Technology:Sermo Report Indicates that Ticagrelor is Likely to Affect the Standard of Care for ACS Patients 2Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients 2Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients 3Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients 4
(Date:3/2/2015)... 2015 Gummy smile reduction expert, ... reshaping can involve one or several procedures to reduce the ... tissue for a more even gum line. Dr. Farnoosh is ... that can permanently lighten discolored or naturally dark gums. ... involves a personalized treatment plan to address a patient’s specific ...
(Date:3/2/2015)... Burns Engineering's Lab-to-Lab Calibration Service offers ... Platinum Resistance Thermometers (SSPRTs) and industrial Resistance Temperature ... . . . guaranteed. Their metrology ... 200706-0), ISO 9001 and 17025 Certified and provides ... to 500°C, both ITS-90 and Callendar-van Dusen calibrations ...
(Date:3/2/2015)... Over the last five years the ultrasound ... to expand their geographic presence and achieve economies of ... $6.2 billion by 2019 at CAGR of 5.1% from ... and Canada and a major part of Europe are ... as Asia-Pacific including China and India, Latin America and ...
(Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s annual awareness ... people across the country to unite, raise awareness, ... their best lives. MS Awareness Week is a special week ... the Society’s vision of a world free of MS. ... the central nervous system, interrupts the flow of information within ...
(Date:3/2/2015)... 02, 2015 Atlantic Information Services, Inc. ... AIS’s Directory of Health Plans: 2015 , the all-new ... the U.S. health plan market, with enrollment data and ... States. , Available as a printed book containing ... trends in quick-view tables and charts, as well as ...
Breaking Medicine News(10 mins):Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2
... 21 Secretary of Veterans,Affairs Dr. James B. Peake ... panels that will make recommendations on ways the Department,of ... prevention,suicide research and suicide education., "There is nothing ... one of,the great men or women who have served ...
... 1 Day ASV Single Vision Lens Now Available Through Licensed Eye Care ... ... Inc. (OTC,Bulletin Board: UVICF; TSX Venture Exchange: UVI), which develops,licenses, manufactures, distributes ... C-VUE(R) 1 Day ASV, which is the,first aspheric, daily disposable contact lens ...
... Leading Pennsylvania Health Insurer Reduce ... DST Health Solutions,today announced an extension of ... health insurer serving nearly 3.4 million,members, for business ... center in Harrisburg, Pa. will,continue to provide business ...
... the Most Promising ... Driving the Future of Technology, SUNNYVALE, Calif., May ... technology in enterprise mobility,today announced that it has won ... most innovative private technology companies based in North,America., ...
... young flight attendant,complains of swelling and tightness in ... her from exercising. Will the ultrasound results indicate,deep ... symptomatology and the frequent presence of comorbidities,make it ... primary care,practice. The Journal of Family Practice has ...
... Thoracic Societys 2008 International Conference in Toronto on Wednesday, May ... young adults. One links low levels of a protein called ... in young women. A second finds that high levels of ... , The data from both studies comes from the ...
Cached Medicine News:Health News:VA Secretary Appoints Panel of National Suicide Experts 2Health News:Unilens Launches Aspheric C-VUE(R) Daily Disposable Lens 2Health News:DST Health Solutions and Independence Blue Cross Extend Business Process Outsourcing Agreement 2Health News:DST Health Solutions and Independence Blue Cross Extend Business Process Outsourcing Agreement 3Health News:Agito Networks Wins Red Herring North America 100 Award Out of More Than 800 Companies 2Health News:Agito Networks Wins Red Herring North America 100 Award Out of More Than 800 Companies 3Health News:CME Publication Gives Clinicians a Leg Up in Treating Disorders of the Lower Extremities 2Health News:Studies provide insights into lung disease and lung function in young adults 2Health News:Studies provide insights into lung disease and lung function in young adults 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: